What is ADMA Biologics's net income?

ADMA Biologics (ADMA) reported net income of $45.33M in Q1 2026.

How has ADMA Biologics's net income changed year-over-year?

ADMA Biologics's net income increased by 68.5% year-over-year, from $26.9M to $45.33M.

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Market cap$2.02B-54.5%

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

What is ADMA Biologics's net income?: ADMA Biologics (ADMA) reported net income of $45.33M in Q1 2026.
How has ADMA Biologics's net income changed year-over-year?: ADMA Biologics's net income increased by 68.5% year-over-year, from $26.9M to $45.33M.